<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509064</url>
  </required_header>
  <id_info>
    <org_study_id>NI17025J</org_study_id>
    <secondary_id>2017-A02858-45</secondary_id>
    <nct_id>NCT03509064</nct_id>
  </id_info>
  <brief_title>Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy</brief_title>
  <acronym>SFINESS-QoLEco</acronym>
  <official_title>The Medico-economic Impact and Quality of Life of the Small-fiber Neuropathy Associated by Using Validated Scales (SF36, DN4, PROFAD SSI, ESPRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LFB BIOMEDICAMENTS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND Sjögren's syndrome is an autoimmune disease whose prevalence is estimated between&#xD;
      200 and 500 patients per 100,000 persons in France (120 to 500,000 patients). It affects&#xD;
      women (90%) between 40 and 60 years of age and main manifestations are generalized sicca&#xD;
      syndrome (ocular, oral, cutaneous) and arthralgia. In 20% of cases, Sjögren's syndrome is&#xD;
      associated with peripheral neuropathies, and the most common form is painful small fiber&#xD;
      neuropathy (SFN). SFNs are mainly featured by neuropathic pain including burns (90%),&#xD;
      numbness (87.5%), tingling (72.5%), electric shocks (70%) and tingling (82.5%) and also&#xD;
      autonomic disorders (50 to 70%).&#xD;
&#xD;
      However, there are still important issues that deserve to be investigated by clinical and&#xD;
      basic research. Among these issues, this study will focus on:&#xD;
&#xD;
        -  The impact of SFN on the quality of life of patients with Sjögren's syndrome.&#xD;
&#xD;
        -  The medico-economic impact of the SFN taking into account the repercussions on the&#xD;
           quality of life, including professional life, usual care cost (analgesics, medical and&#xD;
           paramedical consultations, hospitalizations or emergency).&#xD;
&#xD;
      EXPECTED RESULTS&#xD;
&#xD;
        -  Confirmation of the major impairment in the quality of life of patients with&#xD;
           Sjogren-associated SFN&#xD;
&#xD;
        -  Analysis of correlations to highlight or not clinical or biological factors associated&#xD;
           with quality of life impairment.&#xD;
&#xD;
        -  Evaluation of the cost attributed to the presence of an SFN in patients with Sjögren's&#xD;
           syndrome and the pharmaco-economic interest of conventional therapeutic management&#xD;
           (analgesic treatment, consultation pain) compared to the cost of more aggressive&#xD;
           immunomodulatory treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: Identify the predictors of quality of life impairment and costs of&#xD;
      management of patients with Sjögren's syndrome and small fiber neuropathy (SFN).&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
        1. Hospital, drug and city-care costs&#xD;
&#xD;
        2. Distribution of cost items&#xD;
&#xD;
        3. Part of costs attributable to pSS-associated SFN&#xD;
&#xD;
        4. Loss of quality of life attributable to pSS-associated SFN&#xD;
&#xD;
        5. Relationship between the domains of the EQ 5D questionnaire and the other specific&#xD;
           quality of life questionnaires&#xD;
&#xD;
        6. Association of the EQ 5D and other questionnaires with the costs (part of the costs&#xD;
           variance that might be explained by the quality of life).&#xD;
&#xD;
      PATIENTS AND METHODS / Study population&#xD;
&#xD;
      Monocentric study in the Department of Internal Medicine of Lariboisière Fernand Widal&#xD;
      Hospital.&#xD;
&#xD;
      All included patients fulfilled 2002-criteria of primary Sjogren syndrome.&#xD;
&#xD;
      Patients are classified into 2 arms:&#xD;
&#xD;
      Arm1: patients with Sjögren's syndrome and definite SFN&#xD;
&#xD;
      Arm2 ( Control Group) : patients with Sjögren's syndrome and WITHOUT clinical and&#xD;
      paraclinical arguments for peripheral neuropathy&#xD;
&#xD;
      RESARCH PROCESS&#xD;
&#xD;
      This study will be based on the delivery and analysis of validated questionnaires (collection&#xD;
      sheet) in chronic diseases, pains or Sjögren's syndrome:&#xD;
&#xD;
        -  SF-36 for quality of life,&#xD;
&#xD;
        -  DN4 questionnaire to estimate the probability of neuropathic pain&#xD;
&#xD;
        -  EQ5D Health questionnaire&#xD;
&#xD;
        -  ESSPRI (4 questions): Sjogren-patient questionnaire&#xD;
&#xD;
        -  PROFAD-SSI (19 questions), to assess tiredness, discomfort, pain and dryness symptoms&#xD;
           associated with Sjögren's syndrome.&#xD;
&#xD;
        -  The economic evaluation will be done after the inclusion visit and will be based on the&#xD;
           collection of care resources consumed by the patients during a period of 6 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">July 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of quality of life impairment by SF 36 scale</measure>
    <time_frame>Month 3</time_frame>
    <description>For each of the eight domains that the SF36 measures an aggregate percentage score is produced. The percentage scores range from 0% (lowest or worst possible level of functioning) to 100% (highest or best possible level of functioning).&#xD;
It easy to set up a computerised database (e.g., in MS Excel or similar) to calculate the percentages and averages</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization costs'</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>using a collection sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug costs'</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>using a collection sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>City care costs'</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>using a collection sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of cost items</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>using a collection sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part of costs attributable to primary Sjögren syndrome-associated small fiber neuropathy.</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>using a collection sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of quality of life attributable to primary Sjögren syndrome-associated small fiber neuropathy.</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>The loss of quality of life is appreciated by using a collection sheet (detailed in the research process)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the domains of the EQ 5D questionnaire</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>using a collection sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of specific quality of life questionnaire</measure>
    <time_frame>during a period of 6 months</time_frame>
    <description>using a collection sheet</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Sjögren Syndrome</condition>
  <condition>Small Fiber Neuropathy</condition>
  <condition>Quality of Life</condition>
  <condition>Medico-economic Impact</condition>
  <arm_group>
    <arm_group_label>1: Patients with small fiber neuropathy</arm_group_label>
    <description>patients with Sjogren syndrome have a definite small fiber neuropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Patients without peripheral neuropathy</arm_group_label>
    <description>patients with Sjogren syndrome without signs of peripheral neuropathy (small or large fiber)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection sheet</intervention_name>
    <description>Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet</description>
    <arm_group_label>1: Patients with small fiber neuropathy</arm_group_label>
    <arm_group_label>2: Patients without peripheral neuropathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All included patients fulfilled 2002-criteria of primary Sjogren syndrome.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Definite primary Sjögren syndrome&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  No biologics nor immunoglobulin therapy during the 6 months before study onset&#xD;
&#xD;
        Arm 1: patients with a small fiber neuropathy defined by the presence of a clinical AND one&#xD;
        paraclinical abnormality&#xD;
&#xD;
          -  (i) Clinical signs of small fibers involvement: thermo-algic sensory deficit or&#xD;
             autonomic dysfunction or neuropathic pain with DN4 ≥4;&#xD;
&#xD;
          -  AND&#xD;
&#xD;
          -  (ii) Small fibers neurophysiological abnormalities (QST, laser evoked potentials,&#xD;
             autonomic nervous system tests (sympathetic skin response test or Sudoscan®)&#xD;
&#xD;
          -  OR&#xD;
&#xD;
          -  (iii) abnormal intraepidermal nerve fiber density (skin biopsy)&#xD;
&#xD;
        Arm2 (control group): patients without signs of peripheral neuropathy (small or large&#xD;
        fiber)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of other causes of peripheral neuropathy&#xD;
&#xD;
               -  Acquired: Diabetes, AL amyloidosis, Alcoholism, celiac disease, Drugs, toxic,&#xD;
                  HIV, Sarcoidosis, systemic vasculitis, Guillain-Barré syndrome.&#xD;
&#xD;
               -  Hereditary: Transthyretin hereditary amyloidosis (TTR), hereditary sensory and&#xD;
                  autonomic neuropathy (HSAN), Fabry's disease&#xD;
&#xD;
          -  Patients with impaired thermo-algic sensitivity and / or dysautonomia and / or pain&#xD;
             with DN4 ≥ 4 AND normal diagnostic tests (normal neurophysiological tests AND normal&#xD;
             skin biopsy) are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Damien SÈNE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damien SÈNE, MD, PhD</last_name>
    <phone>+33149956380</phone>
    <email>damien.sene@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Département de Médecine Interne - Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien SÈNE, MD, PhD</last_name>
      <phone>+33149956380</phone>
      <email>damien.sene@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary sjogren syndrome</keyword>
  <keyword>Small fiber neuropathy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Medico-economic impact</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Small Fiber Neuropathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

